GlobeNews Wire

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma…

19 hours ago

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising…

19 hours ago

Nokia Corporation – Managers’ transactions (Hanrahan)

May 31, 2026 06:00 ET  | Source: Nokia Oyj Nokia CorporationManagers’ transactions31 May 2026 at 13:00 EESTNokia Corporation - Managers'…

23 hours ago

Crypto News Today: AlphaPepe Hits $1.38M Raised While Bitcoin Price Prediction Targets $250K

MONACO, May 30, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after the project announced that its…

23 hours ago

Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About

New York City, NY, May 30, 2026 (GLOBE NEWSWIRE) -- The global men’s wellness industry continues to grow rapidly, driven…

23 hours ago

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon…

2 days ago

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants…

2 days ago

ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026

– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients…

2 days ago

Fobi AI Provides Corporate Update Regarding FFCTO Revocation Process and Q3 Interim Filings

May 29, 2026 21:18 ET  | Source: Fobi AI Inc. VANCOUVER, BC, May 29, 2026 (GLOBE NEWSWIRE) -- Fobi” or…

2 days ago